Does Hormone Therapy Actually Improve Aging Skin?
For some skin properties, yes. This systematic review and meta-analysis pooled 15 studies in 1,589 menopausal women, and those studies were a mix of randomized controlled trials and non-randomized clinical trials rather than 15 randomized trials. Menopausal hormone therapy came out ahead of controls for skin elasticity, skin thickness, and collagen content. Skin dryness did not differ significantly between the hormone therapy and control groups.
Dr. Kumar’s Take
The signal here is real but uneven. The pooled effects for collagen content and skin thickness are large and highly significant, while the elasticity effect is small, barely clears statistical significance, and comes with heterogeneity high enough that I would not treat it as settled. Dryness showed no significant benefit at all. My reading is that estrogen acts on the structural side of the dermis, collagen and thickness, more convincingly than on how the skin feels day to day. That matters clinically, because a woman starting hormone therapy hoping her dry skin will resolve is chasing the outcome this analysis failed to demonstrate. The authors themselves close by saying more well conducted clinical trials are needed, and I agree with them.
Study Snapshot
This systematic review and meta-analysis, registered with PROSPERO and conducted under PRISMA 2020 guidelines, searched PubMed, the Cochrane Library, Google Scholar, and ClinicalTrials.gov for studies comparing oral or transdermal menopausal hormone therapy against placebo or another treatment in menopausal women aged 45 to 55. The search returned 1,526 publications, and 15 studies with 1,589 patients entered the final analysis: 845 in the hormone therapy groups and 744 in control or alternative treatment groups. Both randomized and non-randomized clinical trials were eligible, with risk of bias assessed using ROB-2 for randomized studies and ROBINS-I for non-randomized ones. Outcomes were measured by skin biopsy before and after treatment, a computerized suction device, elasticity measurement with an aspiration device, and measurement of skin fold thickness.
Results in Real Numbers
- Skin elasticity: standard mean difference 0.28 (95% CI, 0.03 to 0.54; p = 0.03), pooled from 4 trials covering 251 patients, with heterogeneity of 76%
- Skin thickness: standard mean difference 1.27 (95% CI, 0.88 to 1.66; p < 0.00001), pooled from 3 trials covering 141 patients
- Collagen content: standard mean difference 2.01 (95% CI, 1.42 to 2.61; p < 0.00001)
- Skin dryness: standard mean difference 0.15 (95% CI, -0.05 to 0.35; p = 0.14), not statistically significant
- Elasticity studies were split: of 9 studies assessing elasticity, 6 non-randomized trials and 3 randomized trials, six reported an increase with hormone therapy and three found no significant effect
- Thickness studies were split: four studies showed increased thickness in the treated groups, while two others found no significant difference between baseline and 6 months of treatment in either group
Who Benefits Most
The included studies enrolled menopausal women aged 45 to 55. The authors note that hormone therapy offers more advantages than disadvantages for women under 60 or within 10 years of menopause, which is the standard window for starting it. One prospective cohort followed women for 5 years and found that biological elasticity declined significantly in the 39 untreated women, while the 35 women on hormone therapy showed few changes. In a related analysis, the gain in biological elasticity was most prominent in the subgroup classified as good responders to hormone therapy, at p < 0.001. Both oral and transdermal preparations were represented among the included studies.
Safety, Limits, and Caveats
The elasticity meta-analysis carried 76% heterogeneity, meaning the individual trials disagreed substantially with one another, and its pooled effect was small. The pooled analyses rested on modest patient numbers: 251 for elasticity and 141 for thickness, far fewer than the 1,589 total. Mixing randomized and non-randomized designs raises the risk of bias, which is why the authors applied two separate bias tools. Only English language articles were included. Collagen content was assessed at the left shoulder, not the face, so extrapolating to facial appearance goes beyond what was measured. Dryness, one of the complaints women raise most often, did not improve significantly. The authors state directly that more well conducted clinical trials are required to answer the remaining questions in an evidence-based way.
Practical Takeaways
- Hormone therapy showed significant pooled improvements in skin thickness and collagen content, with the strongest statistics of the four outcomes analyzed
- The elasticity benefit was small and statistically fragile, with wide disagreement between trials
- Skin dryness showed no significant difference between treated and control groups
- The evidence base mixes randomized and non-randomized trials, so treat it as suggestive rather than definitive
- Collagen was measured at the shoulder, so these findings are about skin structure, not facial appearance
- Prescribe and take hormone therapy for appropriate menopausal indications; treat any skin effect as secondary
What This Means for Perimenopause and Menopause Care
The skin is an estrogen-dependent organ, and the review lays out why: as ovarian function declines, sex steroid levels fall, elastic fibers become disorganized, collagen fibers decrease markedly, and skin thickness drops. Those changes produce dryness, delayed healing, and wrinkles. This analysis supports the idea that replacing estrogen counteracts part of that structural loss, particularly collagen content and thickness. It is another line of evidence that menopausal skin change is a tissue-level consequence of hormone loss rather than a purely cosmetic concern, but the case is not yet strong enough to make skin a reason to start therapy.
Related Studies and Research
- Menopause, skin and common dermatoses. Part 1: hair disorders
- Effects of menopause on temperature regulation
- Genitourinary Syndrome of Menopause: A Narrative Review
- Sleep disturbance associated with the menopause
- Episode 27: Perimenopause, Menopause, and HRT - What Every Woman Should Know
FAQs
Which skin measures actually improved with hormone therapy?
Skin thickness and collagen content improved with the largest and most statistically robust effects, both at p < 0.00001. Skin elasticity improved by a smaller margin that just reached significance at p = 0.03. Skin dryness showed no significant difference.
Does skin elasticity decline once hormone therapy stops?
The review reports that biological elasticity significantly decreased off hormone therapy, and in a 5-year cohort the untreated women lost biological elasticity significantly while women on therapy showed little change.
Should I start hormone therapy for my skin?
My answer is no. Hormone therapy is indicated for vasomotor symptoms, genitourinary atrophy, and postmenopausal bone loss, and that is where the decision should be made. The skin findings here are worth knowing about if you are already a candidate, but they are not strong enough to drive the prescription on their own.
Bottom Line
Pooling 15 randomized and non-randomized studies in 1,589 menopausal women, this meta-analysis found that menopausal hormone therapy increased skin collagen content and thickness with strong statistical support, improved elasticity modestly and inconsistently, and did not significantly change skin dryness. The authors conclude that hormone therapy improves skin elasticity, collagen, and thickness, while calling for better trials before the question is considered answered.
